Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials-Reference-Cited by-同舟云学术

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

Published:2016-09-14 Issue:11 Volume:18 Page:1089-1092
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ginsberg Henry¹,Cariou Bertrand²,Orchard Trevor³,Chen Lei⁴,Luo Junxiang⁴,Bastyr Edward J.⁴⁵,Bue-Valleskey Juliana⁴,Chang Annette M.⁴,Ivanyi Tibor⁶,Jacober Scott J.⁴,Hoogwerf Byron J.⁴

Affiliation:

1. Irving Institute for Clinical and Translational Research; Columbia University; New York New York, USA

2. Department of Endocrinology, L'Institut du Thorax; CHU Nantes; Nantes France

3. Graduate School of Public Health; University of Pittsburgh; Pittsburgh Pennsylvania USA

4. Eli Lilly and Company; Indianapolis Indiana USA

5. Division of Endocrinology & Metabolism, Indiana University School of Medicine; Indianapolis Indiana USA

6. Eli Lilly and Company; Budapest Hungary

Funder

Sanofi

Regeneron Pharmaceuticals

Amgen

Merck

Kowa

Resverlogix

AstraZeneca

Boehringer-Ingelheim

Pfizer

Janssen

Bristol-Myers-Squibb

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference22 articles.

1. New insights into the pathophysiology of dyslipidemia in type 2 diabetes;Taskinen;Atherosclerosis,2015

2. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia;Parhofer;Diabetes Metab J,2015

3. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes;Chaudhuri;Diabetes Obes Metab,2011

4. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus;Sinha;Diabetes Obes Metab,2014

5. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects;Henry;Diabetes Care,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver insulinization as a driver of triglyceride dysmetabolism;Nature Metabolism;2023-07-17

2. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids;Journal of Lipid Research;2020-08

3. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus;Diabetes, Obesity and Metabolism;2018-05

4. The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro;The Pharmacogenomics Journal;2017-11-21

5. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins;Journal of Investigative Medicine;2017-11-21